Physician profile
Ellis Mez
NPI 1023029956
$4,598.54
in general payments reported to CMS, 2019-2025
34 companies · $929 in 2025
The $929 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $422 · 2021: $659 · 2022: $694 · 2023: $712 · 2024: $921 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $858.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $477.53 | 2021-2025 | |
| Amgen INC. | $406.79 | 2019-2025 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $379.25 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $369.83 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $364.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $333.09 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.67 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $162.39 | 2019-2025 | Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $117.56 | 2020-2022 | |
| Horizon Therapeutics Plc | $105.49 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.94 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $64.37 | 2021-2025 | |
| Eisai INC. | $59.77 | 2020-2021 | |
| Sanofi Pasteur INC. | $54.97 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $53.62 | 2023-2024 | Onpattro |
| Antares Pharma, INC. | $53.17 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $40.67 | 2023 | Quviviq |
| Exact Sciences Corporation | $37.96 | 2023-2025 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $37.31 | 2019-2021 | |
| Allergan, INC. | $36.88 | 2020 | |
| Sumitomo Pharma America, INC. | $35.59 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $33.50 | 2019 | |
| Nevro Corp. | $27.70 | 2022 | |
| Abbott Laboratories | $24.34 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $23.81 | 2025 | Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $21.63 | 2022 | |
| Esperion Therapeutics, INC. | $21.34 | 2023 | Nexletol |
| Corcept Therapeutics | $19.96 | 2025 | Korlym |
| Hikma Pharmaceuticals USA | $17.42 | 2019 | |
| Genentech USA, INC. | $16.69 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.28 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.00 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $15.18 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellis Mez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.